• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/62

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

62 Cards in this Set

  • Front
  • Back
drugs are available in conventional dosage forms and have no bioequivalence problems
AA
drugs that have actual or potential bioequivalence problems, but the problems have been resolved by adequate scientific evidence
AB
bioequivalent sol’ns and powders for aerosolization (nebulizer)
AN
bioequivalent injectable oil soln’s
AO
bioequivalent injectable aqueous sol’ns and some IV non-aqueous sol’ns
AP
bioequivalent topical drugs
AT
drugs in extended release dosage forms with bioequivalence issues
BC
active ingredients in dosage forms with documented bioequivalence problems
BD
delayed-release oral dosage forms with potential bioequivalence problems
BE
products in aerosol-nebulizer drug delivery systems unless proven bioequivalent
BN
active ingredients in dosage forms with potential bioequivalence problems
BP
suppositories or enemas that deliver drugs for systemic absorption unless proven bioequivalent
BR
products with drug standard deficiencies
BS
topical drug products with bioequivalence issues
BT
products with insufficient data to determine therapeutic equivalence
BX
drugs that cannot be determined for therapeutic equivalence until certain questions are
resolved
B*
Lysergic acid diethylamide
Schedule I
Mescaline
Schedule I
Psilocybin
Schedule I
Methaqualone
Schedule I
Codeine
Schedule II
Cocaine
Schedule II
Meperidine
Schedule II
Dihydrocodeine
Schedule II
Diphenoxylate
Schedule II
Phenmatrizine
Schedule II
Amibarbital
Pentobarbital
Secobarbital
Schedule II
Phencyclidine
Schedule II
Mixed preparation of
Amibarbital
Pentobarbital
Secobarbital
Schedule III
Phenobarbital
Schedule IV
Lysergic acid or methyprylone suppository
Schedule III
Aspirin or Acetaminophen and codeine
Schedule III
Nalorphine
Schedule III
Benzphetamine
Schedule III
Chlorphentermine
Schedule III
Clortermine
Schedule III
Phendimetrazine
Schedule III
Anabolic steroids
Schedule III
Dronabinol
Schedule III
Ketamine
Schedule III
Approved GHB
Schedule III
Paregoric
Schedule III
Dextropropyphene
Schedule IV
May not contain more than:
1.8 g codeine or dihydrocodeine/100 mL, or not >90 mg/dosage unit
Schedule III
May not contain more than:
300 mg dihydrocodeinone and ethylmorphine/100 mL, or not >15 mg/dosage unit
Schedule III
May not contain more than:
500 mg of opium/100 mL or /100 g, or not >25 mg/dosage unit
Schedule III
May not contain more than:
50 mg of morphine/100 mL or 100 g
Schedule III
May not contain more than:
1 mg difenoxin
Schedule IV
More than:
25 micrograms of atropine sulfate
Schedule IV
Chloral hydrate
Schedule IV
Chlordiazepoxide
Schedule IV
Diethylpropion
Schedule IV
Phentermine
Schedule IV
Pentazocine
Schedule IV
Cannot contain more than:
200 mg codeine/100 mL or /100 g
Schedule V
Cannot contain more than:
100 mg dihydrocodeine, ethylmorphine, or opium /100 mL or /100 g
Schedule V
Cannot contain more than:
2.5 mg diphenoxylate, and not <25 μg atropine sulfate/dosage unit
Schedule V
Cannot contain more than:
0.5 mg difenoxin, not <25 μg atropine sulfate/dosage unit
Schedule V
Form 106
Theft of loss of controlled substance
Form 222
Ordering or returning schedule I or II controlled substances to a supplier
Form 224 (a and b also)
Initial registration form for pharmacies, if considered a dispenser

Form 224a: completed by pharmacies for renewal
Form 224b: completed by chain pharmacies for renewal, aka “Retail Pharmacy Chain Affidavit” or blanket renewal
Form 225
Initial registration form for manufacturers, distributors and narcotic treatment program